ArticleOphthalmology and therapy2026
Refractive and Visual Outcomes of SmartSight NOVA Refractive Lenticule Extraction for Myopia and Myopic Astigmatism at 3 Months: a Retrospective Case Series.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSmartSight NOVA using the ATOS platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany) is a refractive lenticule extraction method with CenTrax-assisted centration. We hypothesized that SmartSight NOVA would provide safe, effective, and predictable 3-month outcomes for myopia and myopic astigmatism while maintaining favorable positional stability relative to the preoperative vertex-centered reference and acceptable higher-order aberration profiles.
methodsThis retrospective single-center case series included 84 eyes of 42 patients treated with SmartSight NOVA for myopia and myopic astigmatism. Standard refractive surgery outcome analyses were performed at 1 and 3 months, including visual acuity, manifest refraction, and stability. Higher-order aberrations, chord μ subgroup analyses, and postoperative center-coordinate stability relative to the preoperative position were also assessed.
resultsNo clinically significant intraoperative or postoperative complications were observed during the 3-month follow-up. Preoperative manifest spherical equivalent was -3.70 ± 1.21 D. At 3 months, mean postoperative uncorrected distance visual acuity was 0.006 ± 0.020 logarithm of the minimum angle of resolution (logMAR), and postoperative manifest sphere, cylinder, and spherical equivalent were 0.021 ± 0.311 D, -0.327 ± 0.280 D, and -0.143 ± 0.336 D, respectively. Spherical equivalent was within ± 0.50 diopters (D) in 81.0% of eyes at 1 month and 89.3% at 3 months, and within ± 1.00 D in 100.0% of eyes at both visits. Postoperative refractive astigmatism was ≤ 0.50 D in 86% of eyes and ≤ 1.00 D in 100% of eyes at 3 months. No eyes lost two or more lines of corrected distance visual acuity. Induced higher-order aberrations did not differ significantly among preoperative chord μ groups. Mean displacement magnitude was 0.049 ± 0.028 mm, and 92.9% of eyes were within 0.10 mm of the preoperative position.
conclusionsSmartSight NOVA showed favorable early clinical outcomes at 3 months, with good visual and refractive performance, low residual astigmatism, limited higher-order aberration induction, and small postoperative displacement relative to the preoperative vertex-centered reference in most eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.